Page 4 - Fastpharming Contract Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

[December 28, 2020] iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (“CSO”), effective January 18, 2020. “We are thrilled to have Dr. Brenner join our team,” said Tom Isett, Chairman & CEO of iBio. “Given his prior experience leading organizations with novel protein expression platforms to build proprietary product pipelines, Dr. Brenner should be uniquely suited to assist iBio with a similar transformation. Notably, he also brings a track-record of effective new target search and evaluation, as well as establishing productive collaborations.”

United statesMartinb brennerTom isettStephen kilmerEli lillyFastpharming contract developmentRecursion pharmaceuticals incVeterinary school of hannoverHead of the insulin resistance groupPfenex incWhile the companyCompany annual report on formPfizer incGlycaneering development serviceGood research practiceCompany lilly